MediWound misses Q3 revenue estimates

Mediwound

20/11/2025 12:08

Overview

MediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectations

Adjusted EBITDA loss for Q3 beats analyst estimates

Company strengthens balance sheet with $30 mln equity financing

Outlook

MediWound expects full operational capacity for NexoBrid facility by year-end 2025

Company plans to initiate EscharEx trial for diabetic foot ulcers in H2 2026

Peak sales opportunity for EscharEx estimated at $831 mln

Result Drivers

REVENUE GROWTH - Q3 revenue increased 23% yr/yr, driven by higher development service revenue from U.S. DoD contracts

EXPANDED CAPACITY - Completion of commissioning for expanded NexoBrid facility to increase production capacity sixfold by year-end 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$5.40 mln
$6.65 mln (6 Analysts)
Q3 EPS
-$0.24
Q3 Net Income
-$2.70 mln
Q3 Adjusted EBITDA
Beat
-$5.40 mln
-$10.08 mln (2 Analysts)
Q3 Gross Profit
$900,000
Q3 Operating Income
-$6.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 41.4% above its November 19 closing price of $17.86

Press Release: ID:nGNX4Lq6RT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)